INCB13739
Based on 1 Customer Validation
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.79%
- CAS No.: 869974-19-6
- Formule: C28H25N3O4
- Masse moléculaire:467.52
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B1472
Deoxycorticosterone acetateMineralocorticoid Receptor Agonist -
HY-113414
DeoxycorticosteroneMineralocorticoid Receptor Agonist -
HY-147277
LorundrostatCYP11B2 Inhibitor -
HY-B1472R
Deoxycorticosterone acetate (Standard) -
HY-113151
18-OxocortisolMineralocorticoid Agonist -
HY-17463
PrednisoloneGlucocorticoid -
HY-13580
BudesonideGlucocorticoid Receptor Agonist -
HY-113414R
Deoxycorticosterone (Standard) -
HY-77839
CortodoxoneGlucocorticoid Steroid Hormone -
HY-13600
Clobetasol propionateCYP3A5 Inhibitor -
HY-17463R
Prednisolone (Standard) -
HY-13693
Mometasone furoateGlucocorticoid Receptor Agonist
Activité biologique
Description
IC50 & Target
IC50: 3.2 nM (11β-HSD1 enzymatic), 1.1 nM (11β-HSD1 PBMC)[1]
In Vitro
INCB13739 is >1000-fold selective towards 11β-HSD2, mineralocorticoid receptor (MR), and glucocorticoid receptor (GR)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
INCB13739 (3 mg/kg, IV; 10 mg/kg, PO; once) displays decent oral bioavailability in both rats and cynomolgus monkeys[1].
Pharmacokinetic Parameters of INCB13739 in rats[1].
| IV (3 mg/kg) | PO (10 mg/kg) | |
| Cmax (µM) | 6.46 ± 2.41 | |
| AUC0-24 (ng/mL∗h) | 11.2 ± 3.27 | |
| t1/2 (h) | 1.4 ± 0.2 | 1.2 ± 0.3 |
| CL ((L/h)/kg) | 1.0 ± 0.2 | |
| Vdss (L/kg) | 1.6 ± 0.5 | |
| F (%) | 51 ± 15 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats, cynomolgus monkeys[1]
-
Dosage:3 mg/kg (IV), 10 mg/kg (PO)
-
Administration:IV and PO, once (Pharmacokinetic Analysis)
-
Result:Displayed decent oral bioavailability in both rats (F%=51 ± 15%) and cynomolgus monkeys (F%=43%).
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 869974-19-6
-
Appearance Solid
-
Masse moléculaire 467.52
-
Formule C28H25N3O4
-
Color Off-white to light yellow
-
SMILES
O=C(C1=NC=C(C2=CC=C(C3(C(N4C[C@]5(CC4)OC(C6=C5C=CC=C6)=O)=O)CC3)C=C2)C=C1)NC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 125 mg/mL (267.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Marando C, et al. Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approach. Bioorg Med Chem Lett. 2022 Aug 1;69:128782. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1389 mL | 10.6947 mL | 21.3895 mL | 53.4736 mL |
| 5 mM | 0.4278 mL | 2.1389 mL | 4.2779 mL | 10.6947 mL | |
| 10 mM | 0.2139 mL | 1.0695 mL | 2.1389 mL | 5.3474 mL | |
| 15 mM | 0.1426 mL | 0.7130 mL | 1.4260 mL | 3.5649 mL | |
| 20 mM | 0.1069 mL | 0.5347 mL | 1.0695 mL | 2.6737 mL | |
| 25 mM | 0.0856 mL | 0.4278 mL | 0.8556 mL | 2.1389 mL | |
| 30 mM | 0.0713 mL | 0.3565 mL | 0.7130 mL | 1.7825 mL | |
| 40 mM | 0.0535 mL | 0.2674 mL | 0.5347 mL | 1.3368 mL | |
| 50 mM | 0.0428 mL | 0.2139 mL | 0.4278 mL | 1.0695 mL | |
| 60 mM | 0.0356 mL | 0.1782 mL | 0.3565 mL | 0.8912 mL | |
| 80 mM | 0.0267 mL | 0.1337 mL | 0.2674 mL | 0.6684 mL | |
| 100 mM | 0.0214 mL | 0.1069 mL | 0.2139 mL | 0.5347 mL |
INCB13739 Related Classifications
HY-150701 Related Classifications
Powered by Bioz
Keywords
- INCB13739
- 869974-19-6
- INCB 13739
- INCB-13739
- Glucocorticoid Receptor
- Mineralocorticoid Receptor
- 11β-HSD
- 11beta-HSD
- 11β-hydroxysteroid dehydrogenases
- 11 beta-hydroxysteroid dehydrogenase
- type 2 diabetes
- glucose
- mellitus
- Metabolic syndrome
- Steroid mimetic
- Spiro heterocyclic compounds
- Tissue specific
- peripheral blood mononuclear cell
- PBMC
- Inhibitor
- inhibitor
- inhibit